BackGlobeImmune Overview

GlobeImmune Current Cash

Track GlobeImmune's current cash ($8.7M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$8.69M
↓ 39.44% YoYΔ $-5.66M vs prior year quarter

Peer trimmed avg / median

Loading

GlobeImmune Current Cash History

Loading

GlobeImmune vs. peers: Current Cash Comparison

Loading

GlobeImmune Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

GlobeImmune (GBIM) FAQ

GlobeImmune (GBIM) currently reports a current cash of $8.7M as of March 2016. That compares with $14M in the prior-year period — down 39.4% year over year. Use the charts on this page to explore GlobeImmune's current cash history and peer comparisons.

GlobeImmune's current cash decreased from $14M to $8.7M — a 39.4% year-over-year decrease (period ending March 2016). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GlobeImmune reported $8.7M in current cash as of March 2016. That compares with $14M in the prior-year period — down 39.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $8.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for GlobeImmune, and consider following GBIM for alerts when major investors trade the stock.

GlobeImmune is classified in the Healthcare sector. On current cash, it currently shows $8.7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GBIM with unrelated industries.